NCT01823068View on ClinicalTrials.gov

Vandetanib in Advanced NSCLC With RET Rearrangement

PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

November 3, 2014

Primary Completion Date

December 29, 2014

Study Completion Date

March 16, 2018

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

Vandetanib

Patients will begin on once daily vandetanib at 300 mg with one cycle of 4 weeks.

Trial Locations (2)

110744

Seoul National University Hospital, Seoul

135710

Samsung Medical Center, Seoul

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Samsung Medical Center

OTHER